Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
BioArctic AB (publ)
BIOA-BCurrent price
178.8 SEK
-21.15 SEK (-10.60%)
Last closed
196.7 SEK
Company
www.bioarctic.se
ISIN
SE0010323311
Sector
Healthcare
Industry
Biotechnology
Exchange
Stockholm Exchange
Capitalization
12 520 144 813 SEK
Yield for 12 month
-19.68 %
1Y
3Y
5Y
10Y
15Y
BIOA-B
BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer's disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer's disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain. Further, it develops BAN1503, BAN2802, BAN2803, and AD2603 for the treatment of Alzheimer's disease; ND-BT3814, ND3014, andGD-BT6822 for the treatment of neurodegenerative disease; and PD1601, PD-BT2238, and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden. Address: Warfvinges vag 35, Stockholm, Sweden, 112 51
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
3 229.3 SEKP/E ratio
–Dividend Yield
–Current Year
+623 794 995 SEK
Last Year
+231 181 722 SEK
Current Quarter
+50 475 143 SEK
Last Quarter
+30 014 305 SEK
Current Year
+350 702 220 SEK
Last Year
+155 914 572 SEK
Current Quarter
+45 603 223 SEK
Last Quarter
+27 749 993 SEK
Key Figures BIOA-B
1 year
3 years
5 years
10 years
EBITDA
-75 309 682 SEK
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-5.24 %
PEG Ratio
–
Return On Equity TTM
-9.18 %
Wall Street Target Price
3 229.3 SEK
Revenue TTM
303 136 432 SEK
Book Value
10.65 SEK
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
1742 %
Dividend Yield
–
Gross Profit TTM
157 504 451 SEK
Earnings per share
-1 SEK
Diluted Eps TTM
-1 SEK
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
-8.4 %
Profit Margin
-29.49 %
Dividend Analytics BIOA-B
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
155 %Dividend History BIOA-B
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
10.05.2019
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation BIOA-B
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
285.7143
Enterprise Value Revenue
39.8657
Price Sales TTM
41.302
Enterprise Value EBITDA
1047.7391
Price Book MRQ
13.3033
Financials BIOA-B
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators BIOA-B
For 52 weeks
139.44 SEK
292.05 SEK
50 Day MA
162.79 SEK
Shares Short Prior Month
–
200 Day MA
198.96 SEK
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart